Nevirapine Retard Sandoz

Nevirapine, the active ingredient in Nevirapine Retard Sandoz, is a non-nucleoside reverse transcriptase inhibitor presented as an extended‑release tablet for oral use. It is employed in the management of HIV‑1 infection in adults and adolescents, helping to suppress viral replication as part of combination antiretroviral therapy.

GNH USA supplies Nevirapine Retard Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets European Union marketing authorization requirements and is manufactured under strict GMP conditions to ensure consistent potency and safety.

Nevirapine is a non‑nucleoside reverse transcriptase inhibitor used in antiretroviral therapy for HIV‑1 infection.

- HIV‑1 infection (treatment‑naïve adults and adolescents): Reduces viral load as part of combination antiretroviral therapy. - HIV‑1 infection (treatment‑experienced patients): Provides an alternative regimen when combined with other active agents. - Prevention of mother‑to‑child transmission of HIV‑1: Used in pregnant women as part of prophylactic regimens.

Nevirapine may cause a range of adverse reactions, from mild to severe. Patients should be monitored for any new symptoms during therapy.

Common Side Effects: - Rash: mild skin irritation or redness. - Nausea: occasional upset stomach. - Headache: transient mild headache. - Fatigue: feeling of tiredness. - Diarrhea: loose stools. - Elevated liver enzymes: mild laboratory changes.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Hepatotoxicity: significant liver injury, potentially life‑threatening. - Severe hypersensitivity reactions: including fever, eosinophilia, and organ involvement.

Before initiating therapy, clinicians should assess patient history and monitor laboratory parameters. - Liver function: evaluate baseline enzymes and monitor regularly. - Skin reactions: inspect for rash and discontinue if severe. - Drug resistance: avoid monotherapy to prevent viral resistance. - Pregnancy and breastfeeding: assess risk‑benefit ratio; use only if clearly needed. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Nevirapine can affect the metabolism of other drugs and be affected by concomitant medications.

Major Interactions (Avoid): - Rifampicin: markedly reduces nevirapine levels, compromising efficacy. - Certain protease inhibitors (e.g., ritonavir): may increase nevirapine toxicity.

Moderate Interactions (Monitor Closely): - Hormonal contraceptives: reduced effectiveness, consider alternative methods. - Warfarin: possible alteration of anticoagulant effect, monitor INR. - Antifungal azoles (e.g., fluconazole): may increase nevirapine concentrations.